Investigating genetic variations within a primary tumor and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma. READ MORE
Journal of Clinical Pathways provides highlights from the annual Gastrointestinal Cancers Symposium in San Francisco, California (January 19-21, 2017).
At the second annual Oncology Nurse Advisor Navigation Summit, Teresa Labovich, MSN, RN, OCN, described a method by which gastrointestinal (GI) oncology nurse navigators (ONN) can play a role in improving institutional efficiency and patient outcomes.
Investigating genetic variations within a primary tumor and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma.
Researchers compared the effects of proton beam therapy plus chemotherapy vs traditional radiation therapy plus chemotherapy in older patients undergoing surgery for esophageal cancer.
A recent study compared the effects of multiple adjuvant chemoradiotherapy regimens on overall survival in patients with gastric or gastroesophageal junction adenocarcinoma.
A recent study reports that the cross-sectional location of gastric cancer is associated with long-term survival outcomes of patients as tumor invasion deepens.
Research in Review
Major complications following total gastrectomy for gastric adenocarcinoma can triple the amount of standard hospital costs.
A routinely available blood test can help improve risk stratification and guide additional therapy for stage II colon cancer.
A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety.
A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified.
The National Comprehensive Cancer Network recently released updated guidelines for the management of multiple gastrointestinal cancers.
The National Comprehensive Cancer Network recently released treatment guideline updates for esophageal and esophagogastric junction cancers, involving a systemic therapy in the second-line setting.